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ABSTR ACT: Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are commonly 
administered to treat atherosclerotic cardiovascular disease. Statin use may expand considerably given its potential for treating an array of cholesterol-
independent diseases. However, the lack of conclusive evidence supporting these emerging therapeutic uses of statins brings to the fore a number of 
unanswered questions including uncertainties regarding patient-to-patient variability in response to statins, the most appropriate statin to be used for the 
desired effect, and the efficacy of statins in treating cholesterol-independent diseases. In this review, the adverse effects, costs, and drug–drug and drug–food 
interactions associated with statin use are presented. Furthermore, we discuss the pleiotropic effects associated with statins with regard to the onset and 
progression of autoimmune and inflammatory diseases, cancer, neurodegenerative disorders, strokes, bacterial infections, and human immunodeficiency 
virus. Understanding these issues will improve the prognosis of patients who are administered statins and potentially expand our ability to treat a wide 
variety of diseases.
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Overview of Current Statin Use
Cardiovascular disease (CVD) is the leading cause of world-
wide deaths, with mortality rates of approximately 235 per 
100,000 inhabitants.1 In the vast majority of patients, CVD 
is specifically attributed to atherosclerosis. While the devel-
opment of atherosclerotic CVD (ASCVD) involves a variety 
of biological processes and behavioral factors, high plasma 
cholesterol levels are thought to play a primary causative 
role.2 Thus, the preferred treatment of hypercholesterolemia-
induced cardiovascular-associated diseases, which includes 
ASCVD, involves the use of statins, which are highly effective 
in lowering the cholesterol levels.3
Lovastatin became the first commercially available statin 
medication in 1987 when it was given the United States Food 
and Drug Administration (FDA) approval.4 Since then, the 
use of statins has proven to be advantageous for the primary 
prevention of CVD by reducing the risk and preventing the 
onset of the disease.5 In addition, statins are often used for sec-
ondary prevention as they are effective in slowing disease pro-
gression and reducing cardiovascular-associated morbidities 
and mortalities. In 2013, the American College of Cardiology 
(ACC) and the American Heart Association (AHA) revised 
the existing guidelines to reduce the risk of CVD.3 Since these 
guidelines significantly expand the population of patients eli-
gible for statin therapy, it is likely that statin use will dra-
matically increase.6 An increase in the use of statins is also 
thought to arise from their cholesterol-independent (pleio-
tropic) effects, which have implications in a wide variety of 
disease processes and thus may significantly broaden their 
therapeutic use.7 Given that the patient population thought to 
benefit from the use of statins will likely continue to increase, 
it is imperative that factors associated with statin use such as 
patient costs, their adverse effects (AEs), and their interac-
tions with food and other drugs be thoroughly understood. 
Furthermore, the effectiveness of statins in treating diseases 
other than ASCVD, such as autoimmune/chronic inflamma-
tory diseases, cancer, neurodegenerative disorders, stroke, and 
bacterial and viral infections should be clearly established.
This review summarizes the most recent literature 
regarding traditional statin therapy, their associated pleiotro-
pic effects, and the current and emerging therapeutic applica-
tions of statins. Content within this review may be of value 
for both the medical and research communities in guiding 
efforts toward optimizing patient care and furthering our 
understanding of issues pertaining to the use of statin therapy 
for treating a plethora of disease states.
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Current Therapeutic Applications of Statins
Goals of statin therapy. The prescribed use of statins for 
preventing the onset of ASCVD or slowing its progression is 
supported by decades of preclinical investigations and clinical 
trials.3,8 Here, the relationships between high levels of low-
density lipoprotein cholesterol (LDL-C) and the development 
of ASCVD as well as the effectiveness of statin therapies for 
enhancing patient health outcomes by lowering LDL-C levels 
and reducing the overall incidence and prevalence of ASCVD-
associated mortalities were clearly established. As a primary 
prevention strategy, the use of statins allows high-risk patients 
to maintain normal levels of LDL-C. In patients diagnosed 
with ASCVD, statins are used as secondary prevention as they 
are effective in significantly lowering the LDL-C levels and 
reducing the risk of a fatal cardiovascular event. The categories 
of LDL-C levels as defined by the National Heart, Lung and 
Blood Institute are depicted in Table 1.
LDL and high-density lipoproteins. Lipoproteins are 
particles that play a major role in transporting lipids, in cir-
culation, such as cholesterol and triglycerides.9 Lipoproteins 
are classified primarily according to their density and lipid 
composition and consist of the following seven major types: 
chylomicrons, chylomicron remnants, very low-density lipo-
proteins (VLDL), intermediate-density lipoproteins (IDL), 
LDL, high-density lipoproteins (HDL), and lipoprotein-
(a). Chylomicrons carry dietary triglycerides and esterified 
and unesterified cholesterol from the intestine to the liver. 
While both VLDL and IDL are involved in the transport 
of lipids from the liver to the peripheral tissues, VLDL 
exports primarily triglycerides, whereas IDL exports both 
triglycerides and cholesterol. LDL is highly enriched in 
 cholesterol, transporting the majority of cholesterol found in 
the circulation. HDL transports both cholesterol and phos-
pholipids but reverses the transport of the lipids by carrying 
them from the peripheral tissues back to the liver where they 
are recycled and excreted. The physiological function of lipo-
protein-(a), an LDL particle, has not yet been defined.
LDL-C is often referred to as bad cholesterol due to its 
close association with ASCVD, whereas HDL-C, because of 
its role in reverse cholesterol transport and inverse relationship 
with cardiovascular incidents, is known as good cholesterol.2 
The causal relationship between LDL-C and ASCVD was 
first established by using human genetic analyses.10 Here, 
patients with familial hypercholesterolemia and elevated 
LDL-C levels (due to loss-of-function mutations in the LDL 
receptor) were found to develop early ASCVD. Furthermore, 
patients expressing various forms of additional members of 
the LDL pathway, such as protein convertase subtilisin/kexin 
type 9 (PCSK9), exhibited low LDL-C levels, which corre-
sponded to a reduced risk of developing ASCVD. In addition, 
pharmacological analyses of the effectiveness of statins have 
established a link between statin use and significant reduc-
tions in coronary events regardless of gender.11 Thus, use of 
both genetic analysis and intervention strategies has firmly 
established the importance of targeting LDL-C via the use of 
statins as an effective approach for treating ASCVD.
Alternatives to statin use. While statins have proven to 
be advantageous for lowering the LDL-C levels in the major-
ity of individuals, some individuals fail to respond to treat-
ment (statin resistant) or are prone to developing AEs (statin 
intolerant).12 Patient’s response to statins varies widely with 
reductions in LDL-C levels following the administration 
Table 1. Classification of total cholesterol levels.
TOTAL CHOLESTEROL LEVEL
 
mg
dL




CATEGORY
,200 Desirable
200–239 Borderline high
240# High
LDL (BAD) CHOLESTEROL LEVEL
 
mg
dL




LDL CHOLESTEROL CATEGORY
,100 Optimal
100–129 Near optimal/above optimal
130–159 Borderline high
160–189 High
190# Very high
HIGH (GOOD) CHOLESTEROL LEVEL
 
mg
dL




HDL CHOLESTEROL CATEGORY
,40 Major risk factor for heart disease
40–59 Transitioning to protective
60# Considered protective against heart disease
Note: Adapted from Ref 184.
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of statins ranging from 5% to 70%. Patients who are statin 
resistant do not achieve desired LDL-C target levels even 
when a high dose of a potent statin is administered. Statin 
resistance likely arises from a number of mechanisms including 
polymorphisms in genes involved in cholesterol synthesis and 
metabolism, such as 3-hydroxy-3-methyl-glutaryl-coenzyme 
A reductase (HMGCR) and low-density lipoprotein receptor 
(LDL-R), and those associated with statin pharmacokinet-
ics, such as transporter proteins (eg, ATP-binding cassette 
sub-family G member 2 [ABCG2] and SCLO1B1). Patients 
who are statin intolerant typically exhibit sensitivity to 
statin-induced myopathy and/or liver injury as indicated by 
increases in liver enzyme activity. In both statin-resistant and 
statin-intolerant patients, other avenues of treatment must be 
explored.3 Alternatives to statin therapy include use of cho-
lesterol absorption inhibitors and bile-acid sequestrants; how-
ever, they lack the potency of statins in their ability to lower 
LDL-C levels. The need for more effective LDL-C-lowering 
therapies, particularly for treating very high-risk patients, has 
led to the development of PCSK9 inhibitors.13 However, their 
relatively high cost and the limited data surrounding their 
clinical effectiveness currently prohibits their wide-spread 
use. Thus, current research and clinical efforts will continue to 
focus on developing effective alternatives to statins in patient 
populations where statin therapy is contraindicated.
Additional approaches, including specific dietary recom-
mendations, such as fish and fish oil, and exercise, should be 
also considered.14,15 For example, patients who altered their 
diets and engaged in exercise programs of 10 miles of walking 
or jogging per week showed a more substantial 14%–20% 
decrease in LDL-C levels as compared to those who only 
altered their diets.15 While a number of dietary regimens have 
been designed to decrease LDL-C levels, their effectiveness 
varies extensively. The most stringent diets, such as the AHA 
Step-1 diet, and the Mediterranean diet, only elicit a reduction in 
LDL-C levels by approximately 5%–9%.16,17 Diets such as the 
Ornish diet have the ability to produce more impressive results, 
decreasing serum LDL-C levels by approximately 17%.18 
However, many of these diets may not be realistic in practice 
as they vary considerably from the typical modern American 
diet. The benefits reported with diet alone should be contrasted 
with the benefits of statins as a routine secondary prevention 
(35% cardiac event reduction). Diet and exercise should be 
considered vital to the reduction of high cholesterol and pre-
vention of cardiac events. However, diet and exercise may not 
be able to lower LDL levels to less than 100 mg/dL. In these 
instances, a pharmacologic statin therapy should be main-
tained with the continuation of diet and exercise.
Statin mechanisms of action. The current therapeutic 
goal of statins involves the following mechanisms19 (as illus-
trated in Fig. 1). Statins inhibit HMGCR in hepatocytes. 
HMGCR is the rate-limiting enzyme of the hepatic cho-
lesterol synthetic pathway and converts 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) to melvalonic 
acid—a precursor in the de novo cholesterol biosynthetic pathway. 
Statins reversibly compete with the endogenous substrate, 
Figure 1. Statin mechanism of action. (A) Statins attenuate HMG-CoA reductase enzymatic activity. (B) Intracellular cholesterol reduction. (C) SREBP 
cleavage and translocation. (D) SREBP promotes LDL-R gene expression. (E) LDL-R gene transcribed and translated. (F) LDL-R density is increased on 
cell surface. (G) LDL binding, endocytosis, and subsequent degradation. (H) Intracellular cholesterol increase toward cellular baseline. (I) Plasma LDL 
levels decrease.
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HMG-CoA, for the active site within the reductase. Binding 
of the statin to the active site of the enzyme confers a con-
formational change that attenuates the enzyme’s function. 
Acting as competitive antagonists, the higher affinity statins 
bind to the active site of the enzyme, thereby preventing bind-
ing of the lower affinity endogenous substrate, HMG-CoA 
(Fig. 1A). The resultant conformational change and inhibition 
of HMGCR decreases cholesterol production and reduces the 
intracellular cholesterol stores of the hepatocytes (Fig. 1B). 
In an effort to maintain homeostasis and counteract this 
decline in intracellular cholesterol, a protease is triggered to 
cleave the sterol regulatory element-binding protein (SREBP) 
from its protein precursor in the endoplasmic reticulum. The 
unbound SREBP is subsequently translocated to the nucleus 
(Fig. 1C). In the nucleus, SREBP binds the sterol regulatory 
element (SRE) located within the promoter elements of the 
gene encoding LDL-R (Fig. 1D). Transcription of the LDL-R 
gene is enhanced resulting in increased expression of LDL-R 
mRNA and increased synthesis of LDL-R protein (Fig. 1E). 
The hepatic LDL-R protein undergoes maturation and con-
stitutive exocytosis intended for hepatocyte surfaces (Fig. 1F). 
Free LDL-C binds to the newly synthesized LDL-R lead-
ing to endocytosis and subsequent lysosomal degradation of 
LDL-C within the hepatocyte (Fig. 1G). The internalization 
of LDL-C increases intracellular cholesterol levels and pro-
motes a return to homeostatic levels of LDL-C (Fig. 1H). The 
ultimate effect of this series of events is a reduction in circu-
lating LDL-C levels—elicited in large part by the increase in 
hepatic LDL-R cell surface density (Fig. 1I).
Use of statins for reducing the risk of ASCVD. 
Recently, the ACC and AHA approved the revision of exist-
ing guidelines designed to reduce the risk of ASCVD that 
were based on evidence generated from a series of randomized 
controlled trials.3 While previous recommendations focused 
on specific target levels of LDL-C, the new recommenda-
tions defined patient groups who would most likely benefit from 
moderate- or high-intensity statin therapy. These groups have 
been identified as follows:
i. clinical ASCVD, ie, acute coronary syndromes, or a his-
tory of myocardial infarction, stable or unstable angina, 
coronary or other arterial revascularization, stroke, tran-
sient ischemic attack, or peripheral arterial disease of 
atherosclerotic origin;
ii. primary elevations of LDL-C $190 mg/dL;
iii. age 40–75 years with diabetes and LDL-C 70–189 mg/dL;
iv. age 40–75 years with LDL-C 70–189 mg/dL and esti-
mated 10-year ASCVD risk $7.5%.
As these guidelines are clinically implemented, it is pre-
dicted that 12.8 million additional individuals will now qualify 
for statin therapy.6 As statin use continues to increase, a con-
cern is raised that patients, as well as physicians, may become 
over-reliant on pharmacological methods of controlling high 
cholesterol levels and disregard approaches such as lifestyle 
changes that are beneficial for not only improving cardiovas-
cular health20 but also overall well-being. Lifestyle changes 
such as the elimination of tobacco products, dietary modi-
fications, weight management, exercise, and yoga have been 
shown to be effective in reducing the risk of CVD.21 Thus, it 
is recommended that patients who qualify for statin therapy 
would benefit the most from intervention strategies that would 
include statin therapy coupled with a healthy lifestyle.22,23
Potential AEs associated with statin use. While statins, 
in general, are well tolerated, AEs are reported and include 
muscle pain and damage, increased blood glucose levels, 
which may contribute to type 2 diabetes mellitus (T2DM), 
hepatotoxicity, digestive problems, cognitive effects, and the 
development of rashes or flushing.24 Of these AEs, those 
impacting muscle, blood glucose levels, and liver function are 
thought to be the most clinically relevant.
Muscle pain and damage. Statin-associated muscle symp-
toms (SAMS) are the most commonly reported AEs affecting 
up to 30% of the patient population.25 SAMS typically present 
as muscle pain, soreness, aching, stiffness, etc, and are often the 
source of statin nonadherence or discontinuation. Clinically, 
these symptoms can be defined as myopathy (muscle weak-
ness), myositis (muscle inflammation), myonecrosis (elevated 
muscle enzyme levels), rhabdomyolysis (severe myonecrosis 
with myoglobinuria or acute renal failure) and myalgia (unex-
plained muscle discomfort which encompasses muscle aches, 
soreness, etc). Mild myalgia occurs in 5%–10% of statin users 
annually and is often intermittent. Life-threatening rhab-
domyolysis occurs in only 0.001%–0.005% of patients or 1–5 
of every 1000 statin users annually.24 Concerns related to the 
risk of rhabdomyolysis have led to the removal of cervastatin 
from the market and recommendations that patients who are 
administered high doses of simvastatin (~80  mg) be closely 
monitored.26,27 Statins are thought to adversely impact muscle 
tissue by altering mitochondrial function and cellular energy 
utilization as well as depleting coenzyme Q10 levels.25 Patients 
who are at high risk for developing statin-induced muscle symp-
toms are often those with other comorbidities or who are coad-
ministered other drugs as described in the following section.
Type 2 diabetes. The question of whether statin use sig-
nificantly raises blood glucose levels and contributes to the 
development of T2DM is complicated by the fact that high 
LDL-C, ASCVD, and T2DM share common risk factors.28 
Like ASCVD, behavioral risk factors of T2DM include a life-
style devoid of physical activity, a high calorie diet saturated 
with high trans-fat foods, cigarette smoking, and overweight/
obesity. Other contributing risk factors are socioeconomic and 
include race/ethnicity, culture, and geographical location.29 
Thus, the likely use of statins by patients with T2DM may 
be deleterious with respect to their T2DM-related conditions.
The diabetogenic effects of statins are thought to arise 
from several mechanisms that converge on glucose regulation 
and pancreatic beta cells,30,31 including inhibition of isoprenoid 
Uses of statins in clinical therapeutics 
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synthesis and subsequent inhibition of glucose uptake by beta 
cells, increased uptake of LDL leading to glucokinase inhibition 
(hence blocking glucose conversion to pyruvate), and cytokine-
induced overproduction of nitric oxide (NO) leading to beta cell 
apoptosis. In addition, statins suppress ubiquinone and ATP 
synthesis. These mechanisms may converge or they may in fact 
be mutually exclusive, yet the ultimate effect rendered is one 
that quells insulin release from beta cells.
A thorough review of the literature reveals the follow-
ing three key themes that are important for understanding the 
relationship that may exist between statin therapy and T2DM.
1. Because of the mechanisms discussed earlier, statins may 
raise blood sugar levels. Numerous population-based 
studies have consistently reported that compared to 
patients in the placebo group, a greater number of patients 
receiving statin therapy were subsequently diagnosed 
with T2DM.30–33 While there have been incident cases of 
T2DM in longitudinal, randomized clinical trials within 
a statin therapy group, there is less often a significant 
difference in these incident cases occurring in the treat-
ment group versus the control group. The findings of one 
study revealed that 3% of the treatment group (rosuvas-
tatin) developed T2DM while only 2.4% of the placebo 
group developed the disease (P = 0.01).34 However, those 
patients of the treatment group also had a significant 
reduction in the risk of heart attack (54%), 48% reduced 
risk of stroke, and 20% lower risk of mortality.
2. CVD risk is increased twofold to fourfold in patients 
diagnosed with T2DM.35 In T2DM patients with nor-
mal LDL levels, statins may have a major role in prevent-
ing the long-term negative health effects often associated 
with chronic T2DM. As in the first case, the long-term 
benefits of a therapeutic statin regimen may outweigh 
any undesirable effects.
3. Statins may have a diabetogenic potential through the 
various mechanisms discussed earlier. While new-onset 
T2DM is observed with all statins,33 and associations 
coupled from those observations, a causal relationship 
cannot be implicated as numerous patients of the control 
group (receiving a placebo) also in fact developed T2DM. 
However, it has become widely accepted that this rela-
tionship is dependent on statin type and dose.28,36
It is thought that “statin therapy is associated with a 
slightly increased risk of developing of diabetes.”35 However, 
the risk is low, and when compared to the reduction in coro-
nary events, the benefits of statin therapy outweigh the risk of 
developing diabetes.
Liver function. Statin-induced hepatotoxicity is relatively 
rare, and approximately 3% of patients who take statins develop 
elevated transaminase levels, a marker of liver injury.37 The 
increases in transaminase levels are typically temporary and 
thought to be due to decreased cholesterol levels, increased 
membrane permeability, and leakage of liver enzymes. In a 
recent study, 22 out of 1188 cases of drug-induced liver injury 
were attributed to statin use.38 Here, statin-induced liver 
injury was primarily of mild-to-moderate severity and revers-
ible and was typically observed after months or years of statin 
use. Thus, as endorsed by the FDA, currently marketed statins 
are associated with a very low risk of serious liver injury.
Patient-to-patient variability. Statin-induced AEs exhibit 
considerable patient-to-patient variability due to factors such 
as genetic polymorphisms, coadministration of drugs, sex, 
body size, age, comorbidities, such as diabetes, kidney, and 
liver disease, and the consumption of more than two alcoholic 
drinks per day. Patients thought to be at increased risk for 
developing AEs following statin use are described in Table 2, 
including the elderly who have decreased drug metabolizing 
capacity, increased exposure to multiple drug regimens, and 
decreased muscle mass.39 Others at high risk include human 
immunodeficiency virus (HIV) patients who are susceptible 
to drug–drug interactions involving statins and antiviral 
therapies.40 Specific statins that vary in their potencies and 
pharmacokinetics are recommended and/or contraindicated in 
these different patient populations.
The wide variability in statin plasma levels and statin-
induced responses in patients following a given statin dose 
is linked to polymorphisms of genes involved in the import, 
export, and metabolism of statins.41 Of particular interest 
are cytochrome P450s (cytochrome P4502C9 [CYP2C9] 
and cytochrome 3A4 [CYP3A4]) and drug transporters 
(ie, solute carrier organic anion transporter family member 
1B1 [SLCO1B1], which facilitates hepatic statin uptake and 
the ABCG2 export pump). While CYP2C9 plays a key role in 
metabolizing fluvastatin, CYP3A4 is of more importance in 
metabolizing simvastatin and lovastatin. Patients expressing 
various forms of CYP2C9, with reduced enzyme activity, are 
more responsive to the LDL-C-lowering effects of fluvastatin.42 
Similarly, patients expressing forms of CYP3A4 with reduced 
enzyme activity are more responsive to the LDL-C-lowering 
effects of simvastatin, atorvastatin, and lovastatin.43,44 Further-
more, patients who harbor allelic variations of both CYP2C9 
and hepatic transporters (ie, OATP1B1) may be at high risk 
for developing fluvastatin-induced myotoxicity.45 Finally, in 
patients expressing a SLCO1B1 variant that is defective in 
hepatic statin uptake, high statin plasma levels and elevated 
risks of statin-induced myopathy have been observed.46 In fact, 
a recent study reported that polymorphisms in SLCO1B1 and 
ABCG2, which correspond to impaired transporter function, 
accounted for 90% of the patient variability of rosuvastatin 
plasma levels.47 Taken together, these studies are indicative 
of the significant advances made in our understanding of how 
polymorphisms in drug-metabolizing enzymes and transport-
ers contribute to variations in patient’s response to statins. 
As a result, the decision-making process involved in weigh-
ing the benefits and risks associated with statin use will likely 
continue to improve.
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Statin use is associated with drug–food and drug–drug 
interactions. Statins are involved in a variety of interactions 
with food and other drugs and typically involve inhibition of 
CYP2C9, CYP3A4, and transporters.48 Statin interactions 
may be divided into the following two groups based on their 
metabolic pathways: (1) those metabolized by CYPs; CYP3A4 
(simvastatin, lovastatin, and atorvastatin), and CYP2C9 
(fluvastatin) and (2) those not metabolized by CYPs. While 
both simvastatin and lovastatin are highly involved in drug–
drug interactions, for simplicity, the discussion below will be 
limited to interactions involving simvastatin.
Statins and grapefruit. The most commonly reported 
food–drug interaction involves grapefruit, which contains fur-
anocoumarins, potent CYP3A4 inhibitors.49 Thus, ingestion 
of grapefruit can impair a patient’s ability to metabolize drugs 
like simvastatin, resulting in a significant increase in plasma 
simvastatin levels. For example, the ingestion of grapefruit 
juice (200 mL) can increase simvastatin plasma levels by more 
than threefold.50 In some cases, the statin/grapefruit interac-
tion can result in rhabdomyolysis.51 At this time, however, the 
prevalence between severe, statin-induced AEs and the con-
sumption of grapefruit in the general population is difficult to 
ascertain.
Statins and other drugs. Drug–drug interactions involv-
ing simvastatin have been reported in patients concomitantly 
administered drugs that are potent inhibitors of CYP3A4, 
such as itraconazole, ketoconazole, amiodarone, cyclosporine, 
ritonavir, and indinavir.48 Coadministration of simvastatin 
with antifungals (itraconazole or ketoconazole) can result 
in rhabdomyolysis and acute renal failure.52,53 Similar AEs 
may also arise upon coadministration of simvastatin with 
amiodarone, an antiarrhythmic agent.54,55 In fact, the FDA 
recommends that in patients taking amiodarone, the dose of 
simvastatin should not exceed 20 mg/day. Concerns are also 
expressed in patients treated with simvastatin and cyclospo-
rine, an immunosuppressant.56,57 Here, the high prevalence of 
rhabdomyolysis and acute kidney injury have triggered warn-
ings that the coadministration of these two drugs should be 
avoided. The AEs associated with cyclosporine use involve not 
only its inhibition of CYP3A4 but also a number of influx and 
efflux transporters.58 Finally, rhabdomyolysis has been reported 
when patients were cotreated with simvastatin and HIV pro-
tease inhibitors such as ritonavir and indinavir.40 Because of 
these reported events, the FDA has recommended labeling 
changes for several statins (simvastatin, lovastatin, atorvas-
tatin, and rosuvastatin) to include contraindications, cautions 
against, or limited doses to reflect the risks for interactions 
between these statins and HIV and HCV protease inhibitors.
The costs associated with the use of statins and other 
cholesterol-lowering drugs. Between 2003 and 2012, statin 
use in adults over the age of 40 years has increased from 
18% to 26%.59 With the newer more stringent guidelines, this 
percentage will increase making statins one of the most com-
monly prescribed medications in the United States. Depend-
ing on an individual’s economic status relative to the average 
cost of the prescribed statin as well as constraints that may be 
imposed by certain healthcare plans, statin use may impose a 
significant financial burden. To illustrate this financial strain, 
a comparison of the cost per day between the name brand and 
generic equivalent is provided in Table 3. As shown, statins 
Table 2. Differences in response to statin drugs among different patient populations.
PATIENT POPULATION COMMENTS SPECIFIC DRUG PRECAUTIONS
East Asian Ancestry185 ·	 Asians taking statins have higher serum levels of 
statins such as rosuvastatin than Caucasians
·	 Doses of rosuvastatin should be 
decreased
Elderly39 ·	 Decrease in muscle mass may increase risk of 
myopathy
·	 As age increases, metabolizing enzymes may be 
less functional, increasing AUC and the likelihood 
of more drug–drug interactions
·	 Atorvastatin and rosuvastatin mildly 
increase ethinyl estradiol and norgestrel, 
used in some postmenopausal therapies
hiV40 ·	 Warnings about the protease inhibitors and non-
nucleoside reverse transcriptase inhibitors used 
in highly active anti-retroviral therapy and statins, 
specific to drugs metabolized by CYP3A4
·	 Atorvastatin and rosuvastatin may be 
used with caution
Pediatrics186–188 ·	 Dose-exposure-response relationships are poorly 
defined in children and adolescents
·	 The ontogeny of drug metabolizing enzymes and 
transporters likely impact statin plasma levels 
·	 Statin use should be limited to children at 
highest CVD risk
·	 Only the following statins are approved 
for use: pravastatin at 8 years of age; 
atorvastatin, fluvastatin, lovastatin, rosuv-
astatin, and simvastatin at 10 years of age
Familial hypercholesterolemia 
(FH)188
·	 Potential for myopathic side effects, but risk is 
similar to that of the general population
·	 Patient-dependent, three- to four-drug 
combinations may be used
·	 Minor interactions between statins and 
ezetimine
Chronic Kidney Disease 
(CKD)189
·	 Statins do reduce cardiovascular events in CKD 
(stages I–IV) but not for those with end-stage 
renal disease and receiving hemodialysis
·	 Atorvastatin and fluvastatin are minimally 
excreted by the kidneys
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that are currently available as generics, such as pravastatin 
($1.16 per day), are relatively affordable as compared to those 
sold as the brand name product of statins such as lovastatin 
($21.00 per day). The newly marketed PCSK9 inhibitors 
(alirocumab and evolocumab) are considerably more expen-
sive, approximately $40 per day. Like other monoclonal anti-
bodies, the relative high cost of PCSK9 inhibitors is attributed 
to their complex production.
Comparison of individual statins. While statins are 
often thought of as a singular entity with similar pharmaco-
logical effects, they differ significantly with respect to their 
chemical properties, efficacy, safety, and the frequency and 
type of side effects experienced. Extensive meta-analyses and 
randomized trials have addressed this issue by comparing a 
variety of different statins. Combining the results of these 
studies, along with the cost of each drug as shown in Table 3, 
demonstrates which statin may be the best choice for a par-
ticular patient.
The STELLAR study found that atorvastatin at doses 
between 10 and 80 mg had the highest number of treatment 
discontinuations due to AEs, followed by rosuvastatin, simv-
astatin, and pravastatin (although there was no 80 mg group 
for pravastatin).60 These results coincide with the findings of 
a meta-analysis that simvastatin and pravastatin appear to 
be the most tolerable and safest of the tested statins.61 The 
STELLAR study also found that rosuvastatin had the highest 
average reduction in LDL-C from baseline at 51.06% (albeit 
no reported data at an 80 mg dose), followed by atorvastatin 
at 44.58%, simvastatin at 36.98%, and pravastatin at 24.7%.60
An additional meta-analysis of randomized trials, the 
VOYAGER study, consisting of 32,258 patients, investi-
gated various statin therapies and compared their impact 
on the reduction in LDL-C and triglycerides in patients 
with hypertriglyceridemia—a condition associated with an 
increased risk of CVD. Here, rosuvastatin was found to reduce 
LDL-C on average, by 52% at a lower dose (40 mg) than both 
atorvastatin and simvastatin at a higher dose (80 mg), of which 
showed a mean reduction of 49% and 43%, respectively.62
Narrowing the focus to specific potential AEs, inter-
esting findings surrounding the development of T2DM and 
SAMS, also referred to as muscle AEs, when comparing dif-
ferent statins are revealed. An analysis involving 246,955 indi-
viduals reported that the only AEs with higher odds ratios 
(OR, 1.51) occurring with statin use compared to a control 
were elevated transaminase levels and the development of 
T2DM (OR, 1.09).61 In terms of individual statins, partici-
pants were more likely to develop T2DM when taking ator-
vastatin (OR, 1.17), followed by pravastatin and rosuvastatin 
(OR, 1.16), simvastatin (OR, 1.10), and lovastatin (OR, 0.98). 
Fluvastatin did not have a reported OR for T2DM; however, 
in terms of transaminase elevation, there was a higher odds 
(OR, 5.18) of occurrence, followed by atorvastatin (OR, 2.55), 
lovastatin (OR, 2.03), rosuvastatin (OR, 1.59), simvastatin 
(OR, 1.16), and pravastatin (OR, 1.00).
In addition, a relationship between the potency of statins 
(as defined by the magnitude by which they reduce LDL-C 
levels) and reported AEs has been identified in an analysis 
representing 147,789 cases.63 Here, symptoms relating to 
Table 3. Costs associated with the use of statins and other cholesterol-lowering drugs.
GENERIC 
NAME
BRAND 
NAMES
TYPICAL 
DOSE
ESTIMATED COST 
PER DAY (GENERIC)
ESTIMATED COST PER 
DAY (BRAND NAME)
Statins
Atorvastatin Lipitor 10 mg
20 mg
$2.26
$3.23
$5.65
$8.19
Fluvastatin Lescol, 
Lescol XL
40 mg (BID)
80 mg (SR)
$7.58
$7.00
$11.19
Lovastatin Altoprev 40 mg $2.16* $21.00
pravastatin pravachol 40 mg
80 mg
$1.16*
$2.16*
$6.61
$6.58
Simvastatin Zocor 20 mg
40 mg
$2.29*
$2.19*
$7.39
$7.55
Rosuvastatin Crestor 5 mg
10 mg
NA $6.61
$6.50
Selective cholesterol absorption inhibitors
Ezetimibe Zetia 10 mg NA $7.12
PCSK9 inhibitors
Alirocumab praluent 75 mg every 
2 weeks
NA $40.00
Evolocumab Repatha 140 mg every 
2 weeks
NA $38.63
Note: *Indicates availability at a $4 Prescription Program location. Estimated Costs Per Day Refs 190 and 191.
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rhabdomyolysis and less severe symptoms (ie, myalgia or joint) 
were reviewed. Statins with the highest potency per milligram 
appeared to have the highest AE relative risk. Thus, in a rank-
ing whereby rosuvastatin was designated as 100% relative risk, 
the less potent statins were ranked as follows: atorvastatin 
(55%) . simvastatin (26%) . pravastatin (17%) . lovastatin 
(7.5%) . fluvastatin (% not reported). An exception appears to 
be fluvastatin, a low potent statin with a relatively high relative 
risk of reported AEs (74%).
Ascertaining the best statin to be used for a particu-
lar patient is difficult because of factors associated with the 
patient (the above mentioned patient-to-patient variabilities 
in comorbidities, genetic polymorphisms, coexposure to other 
drugs, etc) and those associated with the individual drug 
properties (ie, lipophilicity, bioavailability, efficacy, potency, 
and the prevalence of certain side effects). Pravastatin does 
not appear to exert an LDL-lowering effect to the extent 
imposed by the other statins, as reported in the STELLAR 
and additional studies.60–62 However, it appears to be one of 
the safest and cheapest options available, followed closely in 
terms of safety and cost by simvastatin, which typically has a 
low monthly generic copayment. While simvastatin appears to 
be the best choice in terms of cost and safety, atorvastatin and 
rosuvastatin may be more effective with respect to their abil-
ity to reduce cholesterol levels but harbor a higher probability 
of exerting an AE and are also more expensive. Thus, it can 
be seen that many factors need to be taken into consideration 
when deciding which statin to administer; it is not a one-size-
fits-all therapy, and instead, the therapy should be tailored to 
the patient in order to accommodate for the aforementioned 
differences yielding an optimal therapy.
It would be remiss to omit studies reporting findings that 
vary significantly from other patient populations, globally. In 
particular, two European studies, the PRIMO survey and 
the STOMP study, retrospectively found that patients tak-
ing simvastatin, atorvastatin, or lovastatin may be at highest 
risk of developing SAMS (18.2, 9.4%–14.9%).64,65 This vari-
ability may be due to the hydrophilic properties of fluvastatin 
and pravastatin, which may limit their muscle penetration.64 
However, we note that fluvastatin’s low association with 
SAMS supports findings in previous studies that use of lower 
potency statins may result in fewer AEs. It is evident that fur-
ther research should be conducted in specific patient popula-
tions, with tightly controlled variables. Retrospective data can 
be skewed by recall bias; therefore, prospective data should 
be obtained through closely monitored randomized control 
trials in order to compare specific AEs (such as SAMS) that 
may result from the use of various statins in defined patient 
populations.
Summary of statin use and ASCVD. Over the past 
30 years, statins have been used as cholesterol-lowering 
medications.4 Up to this point, this review has discussed 
the intended mechanisms of action associated with statins, 
drug–food interactions, and the use of statins as therapeutic 
agents for treating patients with ASCVD or those at risk of 
developing ASCVD. The remainder of this review exam-
ines the pleiotropic effects associated with statins and their 
potential role in abrogating the pathophysiological processes 
involved in other disease states.
Emerging Therapeutic Applications of Statins
Therapeutic expansion of statin use. Recently, the 
scope of statin therapy has expanded with the emergence of 
evidence suggesting that due to pleiotropic effects of statins 
that are not directly associated with their regulation of cho-
lesterol levels, they may prove to be beneficial for treating a 
number of diseases.7,66 The pleiotropic effects associated with 
statins that may impact disease pathophysiology include their 
modulation of immune responses, their enhancement of anti-
inflammatory processes, and their alterations of signaling 
pathways that involve cholesterol intermediates. To date, the 
multitude of diseases linked to the pleiotropic effects of statins 
include multiple sclerosis (MS), inflammatory bowel diseases 
(IBDs), rheumatoid arthritis (RA), systemic lupus erythema-
tosus (SLE), chronic obstructive pulmonary disease (COPD), 
cancer, strokes, Parkinson’s and Alzheimer’s diseases, bacte-
rial infections, and HIV. The following section provides an 
overview of our current understanding of how statins impact 
the onset or progression of these diseases.
Mechanisms by which statins exert their pleiotropic 
effects. The pleiotropic effects of statins were first reported 
in 1995 when it was observed that the benefits of pravastatin 
extended beyond those attributed to the expected lipid-lowering 
effects of statin therapy.67,68 Further investigation revealed 
that statins possessed novel cholesterol-independent effects, 
which included stabilizing atherosclerotic plaques, enhancing 
endothelial function, modulating immune responses, decreas-
ing oxidative stress/inflammation, and inhibiting the throm-
botic response.7,66 While statins may be able to modulate the 
pathophysiology of a variety of disease states, their effective-
ness is currently under considerable debate due to the diver-
sity of the involved molecular mechanisms, the wide range of 
statins’ pharmacokinetic properties, and issues surrounding 
patient-to-patient variability.
Statins are thought to impact disease processes via 
mevalonate-dependent and -independent mechanisms.7,69–72 
Using a variety of cell types including immune,69 tumor,71 
and endothelial72 cells, statins have been shown to alter fun-
damental cell processes by impinging on well-conserved, key 
signaling molecules. In addition to the mechanisms described 
below, those specific to the disease states under discussion are 
outlined in the following sections.
The mevalonate-dependent mechanisms of statins. The 
mevalonate-dependent mechanisms arise from statin inhibi-
tion of HMGCR activity, cholesterol biosynthesis, and protein 
isoprenylation.69–72 The isoprenylation of proteins, a posttrans-
lational modification, is required for membrane-associated 
proteins to form covalent attachments, maintain appropriate 
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subcellular localization, and engage in intracellular trafficking. 
Key isoprenylated proteins are Ras, Rho, and Rac—critical 
GTPases that regulate a variety of biological processes involved 
in determining cell proliferation, fate, and morphology.
The mevalonate-independent actions of statins. The 
mevalonate-independent effects of statins involve their inhi-
bition of a variety of signal molecules including lymphocyte 
function-associated antigen 1 (LFA-1) and intercellular adhe-
sion molecule 1 (ICAM-1).69,70,72 LFA-1 modulates leukocyte 
trafficking and T cell activation, whereas ICAM-1 sustains 
leukocyte adhesion and facilitates migration. Other mevalon-
ate-independent actions of statins include their inhibition of 
signal transduction molecules (v-akt murine thymoma viral 
oncogene homolog [AKT], extracellular signal-regulated 
kinase [ERK]/mitogen-activated protein kinases [MAPK] 
and janus kinase (JAK)/signal transducer and activator of 
transcription [STAT]) and transcription factors involved in 
mediating proinflammatory responses (nuclear factor-kappa 
B [NF-κB], activator protein 1 [AP1], histone deacetylase 
[HDAC], STAT1, STAT3, and STAT4).69,70 In addition, 
statins activate anti-inflammatory responses by enhancing the 
activity of transcription factors such as Kruppel-like  factor 2 
(KLF2) and peroxisome proliferator-activated receptors 
α and β, which suppress NF-κB and AP1 gene activation.
The extent to which the mevalonate-dependent path-
way versus mevalonate-independent pathway contributes 
to the pleotropic effects of statins has undergone increased 
scrutiny.69,70 Early interest in the mevalonate-independent 
pathway was stimulated by the observation that statins are 
inhibitors of LFA-1 and block its ability to interact with 
ICAM-1 and thereby inhibit T-cell migration.73,74 However, 
since excess mevalonate can reverse a statin’s ability to inhibit 
T cell proliferation and function, the importance of statin 
inhibition of LFA-1 is questionable.75,76 Thus, the extent to 
which mevalonate-dependent pathway versus mevalonate-
independent pathway mediates the pleiotropic and anti-
inflammatory actions of statins requires further investigation.
Stains, NO signaling, and cell fate decisions. Importantly, 
statins also impact vascular and immune functions via altered 
NO signaling leading to improved vascular function, inhibi-
tion of leukocyte chemotaxis, and downregulation of leuko-
cyte adhesion and migration at the vascular wall.69,72 Statin 
modulation of NO bioavailability involves the following three 
major mechanisms: direct activation of endothelial nitric oxide 
synthase (eNOS) activity via activation of protein kinases 
(AMP-activated protein kinase [AMPK], AKT, and protein 
kinase A [PKA]), increased eNOS expression via reduction 
in the Rho/Rho-associated protein kinase (ROCK) pathway, 
and stabilization of eNOS mRNA and reestablishment of 
eNOS coupling via upregulation of guanosine triphosphate 
cyclohydrolase (GTPCH).77
The current interest in the pleiotropic effects of statins 
has focused on their ability to modulate cell fate decisions, 
in particular the proliferation and apoptosis of tumor cells71 
and the differentiation and proliferation of T cells.69,70 Statins 
inhibit cell proliferation by inhibiting Ras and Rho proteins 
and stabilizing the levels of cell cycle proteins (p21 and p27).71 
Furthermore, statins induce apoptosis by upregulating pro-
apoptotic proteins (ie, Bax) and downregulating antiapop-
totic proteins (ie, Bcl-2). With respect to T cells, statins block 
T cell activation, migration, infiltration of the target organ, 
differentiation and proliferation, and the ability to secrete pro-
inflammatory cytokines.69,70 Given that the improper type 17 
helper cells (TH17)/regulatory T cells (TREG) balance contrib-
utes to autoimmune and inflammatory diseases, increasing 
efforts are ongoing to devise therapeutic strategies to restore 
this balance.78
Do statins inhibit the onset or progression of autoim-
mune and chronic inflammatory diseases? In many chronic 
disease states, the inflammatory response is absconded from 
its protective role (eliminating a disease stimuli) to a delete-
rious role of damaging tissue and causing organ failure.78,79 
In some diseases, such as MS, the protective versus deleterious 
switch occurs when self-recognizing antibodies and autoimmu-
nity develop. In other diseases, like IBD, it occurs when loss 
of immune tolerance and tissue homeostasis are met with an 
overly aggressive immune response.76 The immune response 
triggered by these initial events has been frequently described 
as dysfunctional or exaggerated and results in chronic and often 
episodic inflammatory conditions. Regardless of the initial 
pathological events, the progression of autoimmune/chronic 
inflammatory diseases typically involves an increase in the 
severity and frequency of inflammatory episodes (or disease 
flares), resulting in persistent exposure to the inflammatory 
milieu causing necrosis and extensive tissue damage. In the 
majority of patients, an overabundance of cells that exert pro-
inflammatory responses (eg, TH1, TH2, and TH17) and a lack 
of those mediating anti-inflammatory responses (TREG) are 
observed.78 Thus, the ability of statins to alter this imbalance 
of TH1, TH2, and TH17 cell populations versus TREG cell pop-
ulations is of particular interest.74
Statins and MS. The pathology of MS involves TH1/TH17 
and cytotoxic CD8 T cells, which contribute to proinflam-
matory conditions and demyelination of axons in the central 
nervous system (CNS).80 As the disease progresses, the neu-
rons degenerate, resulting in the neurological decline asso-
ciated with MS. The first clinical manifestation, clinically 
isolated syndrome, may or may not develop into MS.81 Once 
diagnosed, MS typically presents as one of the following four 
types: primary progressive, secondary progressive, relapsing 
remitting (RRMS), and progressive. RRMS, the most com-
mon clinical presentation, involving approximately 80% of all 
cases, often develops into nonrelapsing secondary progressive 
MS. In animal models of MS, statins inhibit myelin antigen 
presentation, block the activation and differentiation of T cells, 
and reduce the recruitment of leukocytes.80 The neuroprotec-
tive effect of statins may also involve their ability to enhance 
oligodendrocyte differentiation, reduce oxidative damage, 
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improve vascular function by regulation of NO production, 
inhibit coagulation, promote angiogenesis, and modulate the 
peripheral inflammatory response.
In key randomized clinical trials, statin treatment was 
most beneficial to patients with secondary progressive MS 
reducing the rate of atrophy by as much as 43%.82 In patients 
with RRMS, however, conflicting results have been reported, 
which is attributed to either the statin dose or complications 
that may have arisen from their cotreatment with conven-
tional anti-inflammatory agents, either interferon β (IFNβ) 
or methylprednisone.82–87 As a result, uncertainty exists as 
to whether or not the coadministration of statins with either 
IFNβ or methylprednisone is therapeutically beneficial to 
patients with RRMS. A recent meta-analysis of eight ran-
domized clinical trials has reviewed the effectiveness of statin 
therapy (simvastatin or atorvastatin) in MS patients.88 With 
respect to RRMS, statin therapy used as either a monotherapy 
or in combination with IFNβ was not found to be therapeuti-
cally beneficial. With respect to clinically isolated syndrome, 
statins, administered as a monotherapy, were not convincingly 
beneficial. However, with respect to secondary progressive 
MS, some benefit may be achieved from the use of statins.
Statins and IBD. IBD, composed of Crohn’s disease and 
ulcerative colitis, involves a variety of genetic and environmental 
factors, a dysregulated immune response mounted against the 
intestinal microbiota and chronic intestinal inflammation.89 
The majority of studies performed using IBD-relevant animal 
models have found that statin administration alleviates most 
of the observed inflammatory symptoms.90 In patient popula-
tions, statin exposure has been associated with a significant 
decrease in IBD onset, particularly in older (.60 years of 
age) patients.91 Furthermore, in patients diagnosed with IBD, 
statin use was associated with a reduced use of oral glucocor-
ticoids, implying that statins reduced the severity of their dis-
ease conditions.92 Other studies have found that IBD patients 
who were treated daily with statins (atorvastatin) had signifi-
cantly reduced plasma levels of markers of systemic inflamma-
tion (ie, C-reactive protein).93,94
Statins and RA. RA is characterized by chronic inflam-
mation of the joints, synovial hyperplasia, bone destruction, 
joint deformity, and systemic inflammation.95 Patients with 
RA are at an increased risk of mortality, as much as 50%, due 
primarily to increases in CVDs.96,97 A recent meta-analysis 
involving 992 RA patients demonstrated that statin use sig-
nificantly decreased serum levels of inflammatory markers.98 
Furthermore, patients taking statins have a reduced incidence 
of RA,99 and in those taking simvastatin and atorvastatin, 
a reduction in markers indicative of both RA and CVD has 
been reported.100,101 Despite these promising early studies, 
further investigation is needed to supplement the notion of a 
statin as an effective therapy to treat RA.
Statins and SLE. SLE is an autoimmune disease that 
involves aberrant B cell and T cell signaling and dysregu-
lated apoptosis.102,103 The cellular debris that accumulates 
provides a source of autoantigens, which contributes to 
chronic inflammation, formation of immune complexes in 
specific organs, and organ failure. SLE patients are at high 
risk for developing CVD, which is thought to arise from a 
shared pathogenesis.104 However, randomized controlled tri-
als have failed to demonstrate an effect of statin therapy on 
SLE disease activity, despite observed reductions in serum 
C-reactive protein levels.105 Other studies indicate that in 
SLE patients with hyperlipidemia, statins may reduce the risk 
of mortality.106 In some patients, however, the development 
of autoimmune reactions has been noted, particularly when 
either simvastatin or atorvastatin was administered.107,108 
Autoimmune reactions involving these second-generation 
statins may arise from their proapoptotic activities as well as 
a statin-induced shift from TH1 to TH2 immune responses, 
enhanced B cell reactivity, and the production of pathogenic 
autoantibodies. Thus, use of statins for treating SLE holds 
promise, but the possible development of autoimmune reac-
tions in SLE patients requires further scrutiny.
Statins and COPD. The pathology of COPD, an irrevers-
ible and progressive obstruction of airflow, also involves an 
abnormal inflammatory response.109 While statins have been 
considered for use in treating COPD, current guidelines do 
not recommend the use of statins to prevent acute disease 
exacerbations.110 The basis for these guidelines stems from 
the discrepancy between results obtained from retrospec-
tive cohort studies indicating a beneficial effect of statins in 
COPD patients and those from randomized clinical studies, 
which have failed to confirm these findings.109–112
Do statins inhibit the onset and/or progression of 
cancer? The idea that statins may exert anticancer effects 
arose in part from reports that statin use was associated with 
a significant reduction in colorectal cancer incidences113 and 
a reduction in mortality associated with 13 different cancer 
types.114 However, as discussed in more detail below, epidemi-
ological and clinical studies have thus far failed to consistently 
substantiate claims that statins are effective chemopreven-
tive/chemotherapeutic agents but instead have underscored 
the complexities associated with the development and treat-
ment of human cancers. Our analysis of statins and cancer 
will be limited to cancers of the colon, breast, and prostate 
as these are among the top five most commonly diagnosed 
cancers worldwide.115 Furthermore, the analyses of the impact 
of statins on the onset, progression, and cancer-specific mor-
tality of colorectal, breast, and prostate cancers are relatively 
extensive. The steroid responsive cancers (breast and prostate) 
are of particular interest as both the disease etiology and ther-
apy hinge on the activities of estrogen and androgen, respec-
tively, which may be modulated by statins within the breast 
or prostate tumor cell. By comparing and contrasting the 
impact of statins on the onset and progression of these three 
cancer types, we aspire to identify commonalities and major 
mechanistic pathways that may be relevant to the majority of 
human cancers. 
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Statins as potential chemopreventive agents. The question of 
whether statin use prevents the onset of colorectal, breast, or 
prostate cancers is confounded by the contradictory nature 
of the reports from observational studies. For example, the 
impact of statin use on colorectal cancer incidence has been 
widely studied for more than a decade.116 Despite this, a recent 
meta-analysis representing more than 8 million patients and 
employing a variety of methodological approaches has failed to 
convincingly and consistently demonstrate that long-term use 
of statins prevents the onset of colorectal cancer. Perhaps more 
troubling are reports indicating that statin use may increase 
the risk of colorectal cancer.117 Similar contradictory findings 
have been reported with respect to the impact of statin use 
on breast cancer incidences where an analysis of more than 
77,000 women found that the risk of developing breast cancer 
was not associated with statin use regardless of use duration.118 
Others report that extended statin use is associated with an 
increased risk of developing breast cancer.119 With respect to 
prostate cancer, the evidence pertaining to statin use is simi-
larly contradictory. Some studies report that statin use is not 
associated with the risk of developing prostate cancer.120,121 
Others report that statins may decrease the risk of developing 
low-grade, early-stage prostate cancer but not advanced stage 
prostate cancer.122 In contrast, yet others report that statin use 
was not associated with a decrease in overall risk of prostate 
cancer but rather a decrease in the risk of developing advanced 
prostate cancer.123,124
In addition to preventing the onset of cancer, statins 
have potential for inhibiting cancer metastasis and improving 
patient survival. Thus far, reports from phase II/III clinical 
trials indicate that statin use does not improve progression-
free survival of patients who have been diagnosed with meta-
static colorectal tumors.125,126 With respect to breast cancer, 
some studies have found no association between statin use and 
breast cancer mortality,127 while others suggest that statins 
may decrease breast cancer mortality128,129 particularly, if the 
most lipophilic statin, simvastatin, had been administered.130 
However, reports focused on prostate cancer are more opti-
mistic with some studies suggesting that statins attenuate 
prostate cancer progression131,132 and mortality.133–135
A number of issues may contribute to the contradic-
tions surrounding the question of whether statins are effective 
anticancer agents. First, is the timing of the events associated 
with the development of a tumor relative to the duration of 
statin use. The majority of human tumors are likely caused 
by a series of mutational events that sequentially occur over 
a span of 20–30 years depending on the affected genes and 
involved cellular processes.136 Thus, a statin may effectively 
modulate the relatively modest changes in cellular processes 
that form within a cell of an emerging tumor (ie, within years 
1–10 of tumor development) but may lack potency in over-
coming the plethora of metabolic and cellular processes that 
exist within a fully developed tumor at the end of this 20- 
to 30-year period. Second, the role of cholesterol in tumor 
development is undefined and may present an indication bias 
when statins are used to treat high cholesterol.137 The available 
evidence indicates that high blood cholesterol (an indicator 
for the  administration of statins) may be associated with a 
decrease in colorectal cancer incidence137 but an increase in 
prostate cancer incidence.138 Third, cancer is a highly het-
erogeneous disease composed of distinct subtypes that likely 
determine a patient’s tumor development and response to a 
particular drug therapy or chemopreventive agent.139
It is possible that only a specific tumor subtype can 
respond to the anticancer effects of statins. With respect to 
colorectal tumors, molecular subtyping aligns with tumor 
progression involving activation of oncogenes (ie, Kirsten rat 
sarcoma viral oncogene homolog [KRAS]) and inactivation of 
tumor suppressor (ie, adenomatous polyposis coli [APC]) and 
DNA repair genes. In IBD patients, tumor development is 
also influenced by the chronic inflammatory conditions within 
the colon.140 With respect to breast cancer, molecular subtyp-
ing relies on tumor expression of estrogen receptor (ER), pro-
gesterone receptor (PR), and human epidermal growth factor 
2 (HER2). Ongoing molecular characterization of prostate 
cancer includes aberrant androgen receptor signaling, as well 
as genes such as ETS protooncogene (ETS), KRAS, phos-
phatidylinositol 3-inositol (PI3K)/AKT, phosphatase and ten-
sin homolog (PTEN), and tumor suppressor p53 (TP53).141 
Studies examining the impact of statin use on breast cancer 
subtypes indicate that statins may increase142 or decrease143 the 
risk of developing ER-negative breast cancers or may increase 
the risk of developing PR-negative breast cancer.144 However, 
others report that statin use is not associated with incidence 
regardless of the breast cancer subtype that has developed.145 
Whether or not statins impact specific subtypes of colorectal 
and prostate tumors is yet to be determined.
Putative chemopreventive mechanisms of statins. Efforts 
focused on identifying patients most likely to respond to the 
anticancer effects of statins have uncovered a few important 
underlying genetic and mechanistic events. For example, 
patients who harbor a form of HMGCR that is less effective at 
binding statins appear to be less responsive to a statin’s ability 
to reduce the onset of colorectal cancer.146 Furthermore, in 
patients undergoing androgen deprivation therapy, the ability 
of statins to delay prostate tumor progression appeared to 
involve statin interaction with solute carrier organic anion 
transporter family member 2B1 (SLCO2B1).131 It is proposed 
that by interacting with the SLCO2B1 transport protein, 
statins competitively displace androgens, thereby preventing 
their entry into the tumor cell and inhibiting their protu-
morigenic activities. Similar events may occur in breast cancer 
patients and thereby alter their response to antiestrogens, 
since estrone 3-sulfate, a component of the estrogen pool, is 
also subject to SLCO2B1 transport.147
Attempts to identify appropriate biomarkers to assess the 
chemotherapeutic effectiveness of statins include a clinical 
trial, wherein a relatively high statin dose (ie, 80  mg/day) 
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resulted in a decreased tumor expression of Ki67, a marker 
of proliferation, and a corresponding decrease in serum 
cholesterol levels.148 Additional suggested biomarkers include 
high sensitivity C-reactive protein, estrone sulfate,149 and 
proteins involved in apoptotic pathways.150 These types of 
clinical trials are invaluable for improving our ability to pre-
dict how statins may alter the progression of breast cancer, 
determine the extent to which individual breast cancer 
patients may respond to the statin administration, and iden-
tify appropriate biomarkers for examining their effectiveness. 
Whether or not these findings are applicable to other cancer 
types remains to be seen.
Should statins be used to prevent strokes. Strokes occur 
when blood flow to the brain is restricted, resulting in neu-
ronal cell death.151 This cell death often leads to the symp-
tomatic dysfunction of parts of the body controlled by the 
affected brain regions. Strokes occur in the following two 
main forms: ischemic (more common) and hemorrhagic. The 
former is caused by a deficiency in blood flow characterized by 
blockage, whereas the latter is caused by damaging pressure 
produced by the bleeding of arterial blood vessels in the brain. 
Ischemic stroke can also be further subdivided into the fol-
lowing two causal categories: embolic stroke and thrombotic 
stroke. Thrombotic stroke is often associated with hypercho-
lesterolemia and atherosclerosis and is caused by the formation 
of a blood clot in an artery that supplies the brain.152
While statins have been considered for use in prevent-
ing the onset and severity of stroke, an analysis of the litera-
ture has produced weak and often inconsistent associations 
between stroke and hypercholesterolemia.153 The inherent 
heterogeneity in the disease may be the likely culprit of these 
inconsistencies, as stroke has various etiologies.154 However, 
it has been shown that statin-induced reduction in cholesterol 
concentrations decreases the risk of stroke in high-risk patient 
populations (ie, those with established coronary artery disease, 
hypertension, diabetes, or a high vascular risk).154,155 A meta-
analysis155 revealed that each 1 mM decrease in LDL choles-
terol compared to a 21.1% overall reduction in the relative risk 
for stroke. These results were mirrored by an additional study 
showing a consistent 17%–21% reduction in incident stroke 
risk when patients were put on a statin regimen.154
A multitude of recent experimental studies156–158 have 
pointed to a decrease in mortality risk with statin therapy 
when rendered both before and after the onset of stroke.159 
This decline in mortality risk may be attributed to the neu-
roprotective and neurorestorative effects of statins during 
the onset of an ischemic stroke and after, respectively.160–164 
Furthermore, studies have shown that statin treatment has led 
to improvement in short-term and long-term poststroke qual-
ity of life and survival—these results may even be modulated 
by the stroke severity.153,156,160–164 However, due to the incon-
clusive and discordant nature of some reports, more research 
must be conducted to validate the efficacy of statin therapy on 
stroke prevention and recovery.
Should statins be used to treat neurodegenerative 
disorders? The use of statins to treat a number of neurode-
generative disorders, including Parkinson’s and Alzheimer’s 
diseases, has also been reported.165,166 The pathophysiology 
of Parkinson’s disease involves aggregation of alpha-synuclein 
(α-S), a presynaptic, neuronal protein, which normally binds 
to plasma membranes.167 In addition, high cholesterol levels 
are implicated in disease progression and the use of statins in 
animal models of Parkinson’s disease can reduce α-S aggre-
gation and neuropathology.168 While some epidemiological 
studies report that statin use may reduce the risk of Parkinson’s 
disease,169 others imply that these protective effects are not 
observed after adjusting the results for cholesterol levels.170
With respect to Alzheimer’s disease, high cholesterol 
levels are associated with disease progression and the appear-
ance of plaques, a key characteristic of Alzheimer’s disease.171 
Despite promising results performed in animal models, the 
results from two randomized clinical trials failed to demon-
strate a difference in cognitive decline in patients who were 
receiving statin treatment (simvastatin and/or pravastatin) for 
at least 12 months as compared to the placebo control.172 Due 
to inconclusive evidence, statins and their role in the preven-
tion and treatment of neurodegenerative diseases require fur-
ther investigation.
Should statins be used to treat bacterial infections? The 
ability of statins to modulate the immune and inflammatory 
responses may abrogate the pathogenesis of diseases, such as 
tuberculosis, sepsis, listeriosis, and infections of the host by 
a bacterial entity.173–177 With respect to bacterial infections, 
statins appear to modulate the expression of extracellular recep-
tors involved in the attachment and uptake of certain bacte-
ria. As shown in studies using Pseudonomas aerginousa, statins 
can impede bacterial motility and biofilm production as well 
as attenuate the secretion of proinflammatory cytokines.176 
Additional studies have been performed on several bacterial 
species, which have yielded consistent results.173,175 For exam-
ple, a study involving Mycobacterium tuberculosis, the causative 
agent of most cases of tuberculosis, found that statins coun-
teracted the bacteria’s ability to inhibit immune cell matu-
ration.173 Similarly, when statins were administered prior to 
infection with Listeria monocytogenes, the ability of the bac-
teria to escape phagosomes was inhibited, which diminished 
their evasion of the immune response.175 Although the precise 
mechanisms by which statins modulate the immune system 
in response to bacterial infections are unknown, these studies 
highlight the potential for the use of statins in the prevention 
and treatment of bacterial infections.
Should statins be used to treat patients with HIV-1? 
Antiviral therapy is used extensively to treat individuals with 
HIV-1.178 While pharmacologic agents, such as HIV-1 prote-
ase and nucleoside reverse transcriptase inhibitors, are effective 
at suppressing viral replication, their use is often accompa-
nied by abnormal fat redistribution, peripheral fat wasting, 
central adiposity, and elevated cholesterol and triglyceride 
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concentrations.179 Thus, statins are often administered to HIV 
patients to reduce their cholesterol levels and normalize their 
body composition.180,181 Statins may also reduce HIV-1 infec-
tion, presumably via inhibition of protein prenylation, down-
regulation of Rho activity, and rearrangement of the actin 
cytoskeleton, which prevents HIV-1 from gaining entrance to 
the host cells.182,183 In a recent clinical study, statin admin-
istration to patients chronically infected with HIV-1 sig-
nificantly reduced serum viral RNA loads. However, upon 
discontinuation of statin therapy, viral load rebounded. These 
data imply that future clinical studies should be conducted to 
further assess the use of statins as antiviral agents.
Conclusions
To fully understand whether statins display desirable pleiotro-
pic effects and/or should be used as novel or adjunct therapies 
to treat various diseases—aside from hypercholesterolemia—a 
number of steps should be considered. First, the patients who 
are most likely to positively respond to the desired effect of 
statins must be identified. Second, the most effective dose, 
duration of use, and statin drug entity to be used must be 
clinically established. Third, biomarkers accurately reflecting 
the pleiotropic actions that are clearly indicative of a patient’s 
response to the statin and are specific for the disease state of 
interest should be identified. Successful completion of these 
endeavors would then culminate in randomized clinical trials 
designed to evaluate the purported efficacy of various off-label 
effects of statins.
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